Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Your health is our top priority and we want to ensure that you are accessing — and not delaying — the care you need.
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
The field of epilepsy has seen great strides in the last couple of decades.